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S U M M A R Y
Objectives: To determine the prevalence of smoking and alcohol abuse among patients with invasive
pneumococcal disease (IPD) in order to promote prevention strategies.
Methods: We prospectively studied all culture-proven IPD cases in patients aged 18 years during the
period 1997–2011. The habits of smoking and alcohol abuse were evaluated. Pneumococcal serotyping
was performed.
Results: There were 1378 IPD cases, with a mean age of 61  17 years; 65% were males. Compared to the
general population aged 18–64 years, patients with IPD of the same age group were more often current
smokers (57% vs. 35%, p < 0.001) and alcohol abusers (21% vs. 6%, p < 0.001). Among patients with IPD, young
adults (aged 18–49 vs. 50–64 vs. 65 years) were more commonly current smokers (71% vs. 40% vs.14%, p <
0.001) and alcohol abusers (23% vs. 18% vs. 6%, p < 0.001). Males were more frequently smokers and alcohol
abusers than females. Smokers and alcohol abusers more often had underlying diseases such as HIV infection
and chronic liver disease. Pneumonia was more common in smokers and peritonitis in alcohol abusers.
Alcohol abuse conferred higher mortality. Certain pneumococcal serotypes, such as serotypes 1, 8, and 23F,
more frequently caused IPD in smokers, and serotypes 4, 11A, and 19F in alcohol abusers.
Conclusions: Smoking and alcohol abuse are the most preventable risk factors for IPD. Implementing
smoking and alcohol abuse cessation programs and a pneumococcal vaccination schedule are essential
to diminish the burden of pneumonia and other pneumococcal infections.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
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Invasive pneumococcal disease (IPD) remains an important
health problem worldwide. The main clinical manifestations are
pneumonia, meningitis, and primary bacteremia.1
Although healthy adults may suffer from IPD, it occurs more
often in the elderly and in patients with underlying diseases, which
are known risk factors for IPD.2,3 In addition, several studies have
shown that smoking4–8 and alcohol abuse9–11 are important risk
factors for overall pneumonia, pneumococcal pneumonia, and
other pneumococcal infections. Active and passive smoking may§ This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-ShareAlike License, which permits non-
commercial use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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http://dx.doi.org/10.1016/j.ijid.2013.12.013enhance the adherence of pneumococci to epithelial cells and
increase oropharyngeal colonization and pneumococcal infec-
tions;12–14 alcohol abuse may alter several mechanisms of the host
immune response and predisposes to overall pneumonia and
pneumococcal infections.15–19
The current US Centers for Disease Control and Prevention
(CDC) recommendations for vaccination of adults with pneumo-
coccal polysaccharide vaccine, PPV23, advise vaccination of
those aged 65 years, younger adults with known underlying
diseases, and people who are alcohol abusers and current
smokers.20 The recently introduced pneumococcal conjugate
vaccine, PCV13, is licensed by the US Food and Drug Administra-
tion (FDA) for use in persons aged 50 years, and the CDC
recommendations also include younger adults with speciﬁc underly-
ing conditions.20
Although many reports have identiﬁed that smoking and
alcohol abuse are common among patients with pneumococcal
infections, to our knowledge there is no report with a detailedn behalf of International Society for Infectious Diseases. All rights reserved.
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regard to smoking and alcohol abuse habits in patients with IPD.
The main objectives of this study were: (1) to determine the
prevalence of smoking and alcohol abuse among adult patients
with IPD stratiﬁed by age and sex, and (2) to analyze the main
underlying diseases, clinical presentations, prognosis, and pneu-
mococcal serotypes in smokers and alcohol abusers with IPD.
2. Methods
We have prospectively studied and included in a computerized
protocol all patients suffering from IPD who have been seen at
Bellvitge Hospital, a tertiary teaching hospital in Barcelona, over
recent decades.21,22 For the present study we included all culture-
proven IPD cases in adult patients aged 18 years who were seen
during a 15-year period (1997–2011). Overall, there were 1404
patients with IPD; 26 of them were excluded because there was no
information available about smoking or alcohol consumption.
Therefore, a total of 1378 IPD patients were eligible for inclusion in
the study.
Most of the methodology and deﬁnitions used in this study have
been reported previously.3 In brief, a diagnosis of IPD in a
symptomatic patient was made if Streptococcus pneumoniae was
isolated from a normally sterile body ﬂuid, such as blood, pleural
ﬂuid, cerebrospinal ﬂuid, or peritoneal ﬂuid. For example, invasive
pneumococcal pneumonia was diagnosed if a new pulmonary
inﬁltrate was present on a chest radiograph together with the
isolation of S. pneumoniae from blood or pleural ﬂuid culture.
Nevertheless, it is well known that most pneumococcal pneumonia
cases do not have positive blood cultures; these cases are not
included in the present study. Other clinical manifestations, such
as meningitis and peritonitis, were diagnosed based on standard
criteria. Alcohol abuse was considered when the patient reported a
daily alcohol intake of 80 g for men or 60 g for women, during at
least the 12 months prior to inclusion in the study. For instance,
one beer of 0.25 l (5% alcohol by volume, 12% ABV) contains 10 g
alcohol. A patient was deﬁned as a current smoker when they had
smoked at least 10 cigarettes per day during the year prior to
inclusion in the study.
We considered several underling immunosuppressive and
chronic diseases in patients with IPD: HIV infection, malignancies,
chronic pulmonary disease, chronic liver disease, diabetes,
cardiovascular disease, chronic renal failure, and vascular or
degenerative brain disease. A more detailed description is reported
elsewhere.3
Antibiotic therapy was prescribed in accordance with the
hospital guidelines. The standard regimen for pneumonia con-
sisted of ceftriaxone, levoﬂoxacin, or a macrolide, alone or in
combination. Meningitis was treated with cefotaxime with or
without vancomycin. Mortality was considered when the patient
died within 30 days of diagnosis.
The institutional review board – Comite´ E`tic d’Investigacio´
Clı´nica de l’Hospital de Bellvitge – approved this study and
publication of the results. The need for informed consent was
waived as the study analyzed data retrospectively and the data
were anonymized.
2.1. Microbiological methods
Streptococcus pneumoniae strains were identiﬁed by convention-
al methods (optochin susceptibility and bile solubility). Pneumo-
cocci were serotyped by dot-blot assay or Quellung reaction at the
Spanish Reference Laboratory, Majadahonda, Madrid, Spain.
In our geographical area (Catalonia), vaccination with the
23-valent polysaccharide pneumococcal vaccine (PPV23) was
recommended for people over 65 years of age starting in 1999,and according to some reports, around 60% of older adults have
received the PPV23.23,24 The introduction of the PCVs into the
childhood vaccination schedule was as follows: PCV7 in 2001,
PCV10 in 2009, and PCV13 in 2010. PCV13 was introduced for
adults in September 2012. The serotypes included in PCV13 are: 4,
6B, 9 V, 14, 18C, 19F, 23F, 1, 5, 7F, 3, 6A, 19A. In our area, more than
50% of young children have received PCV7.25
2.2. Statistical analysis
The statistical analysis was carried out using IBM SPSS Statistics
for Windows, version 20.0 software (IBM Corp., Armonk, NY, USA).
The Chi-square test or Fisher’s exact test was used for categorical
variables (two-by-k contingency tables) and the Student’s t-test for
continuous variables. In order to analyze the association of
pneumococcal serotypes with smoking or alcohol abuse, we used
a logistic regression model. We chose serotype 3 as the reference,
since it was the most prevalent and because the proportions of
smoking and alcohol abuse among patients infected with this
serotype were near the average obtained for all IPD patients. We
constructed a multivariate logistic regression model to investigate
the association of alcohol abuse and smoking habit with mortality,
after adjusting for factors such as age, sex, underlying disease,
clinical manifestation, and shock at presentation. Adjusted odds
ratios (OR) and 95% conﬁdence intervals (95% CI) were calculated.
Data on the rates of current smokers and alcohol abusers in the
general population were obtained from the public database of the
Agencia de Salut Publica de Catalunya on the Web ‘‘Ofﬁcial
statistics in Catalonia, year 2011’’.26 We compared the prevalence
of smoking and alcohol abuse between patients with IPD and the
general population of the same age group and the same period of
time. All p-values were two-tailed and p < 0.05 was considered
statistically signiﬁcant.
3. Results
We studied 1378 adult patients with IPD. The mean age
( standard deviation) was 61  17 years (range 18–97 years) and
65% were males. The main clinical manifestations were pneumonia
(n = 1059; 77%), meningitis (n = 120; 9%), and peritonitis (n = 72; 5%).
3.1. Prevalence of smoking and alcohol abuse
Overall, 498 (36%) patients with IPD were current smokers and
188 (14%) were alcohol abusers. Of note, 29% (142 of 498)
of patients who smoked were also alcohol abusers, and 76% (142 of
188) of patients who abused alcohol were also current smokers.
Younger adults with IPD were more frequently current smokers
than older adults (71% aged 18–49 years, 40% aged 50–64 years,
and 14% aged 65 years, p < 0.001). Figure 1 shows that males
were more frequently smokers than females (males vs. females):
75% vs. 63% aged 18–49 years, p = 0.027; 47% vs. 29% aged 50–64
years, p = 0.002; and 21% vs. 3% aged 65 years, p < 0.001 (44% vs.
22% for all ages, p < 0.001).
In addition, younger adults with IPD were also more frequently
alcohol abusers than older adults (23% aged 18–49 years, 18% aged
50–64 years, and 6% aged 65 years, p < 0.001). Figure 1 shows
that males were more frequently alcohol abusers than females
(males vs. females): 29% vs. 8% aged 18–49 years, p < 0.001; 25% vs.
7% aged 50–64 years, p < 0.001; and 9% vs. 1% aged 65 years,
p < 0.001 (19% vs. 4% for all ages, p < 0.001).
Compared to the general population aged 18–64 years in our
geographical area,23 patients with IPD of the same age group were
more often (p < 0.001 for all) current smokers (57% vs. 35%; males
62% vs. 41% and females 45% vs. 29%) and alcohol abusers (21% vs.
6%; males 27% vs. 9% and females 7% vs. 3%).
Figure 1. Percentage of current smokers and alcohol abusers among 1378 adults
with invasive pneumococcal disease according to age and sex.
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Table 1 shows the clinical characteristics of 1378 patients with
IPD divided into four categories: those who smoked (n = 357; 26%),Table 1
Characteristics of 1378 invasive pneumococcal disease (IPD) episodes in current smok
Control group
(n = 834)
Smokers
(n = 356)
p-Valueb
Age, years, mean  SD 67.9  14.9 49.4  16.4 <0.001 
Sex, n (%)
Male 461 (55) 264 (74) <0.001 
Female 373 (45) 92 (26) 
Underlying diseases (1), n (%) 684 (82) 294 (70) <0.001 
Main underlying diseases, n (%)
Chronic liver disease 63 (8) 44 (12) 0.008 
HIV infection 16 (2) 92 (26) <0.001 
Chronic pulmonary disease 185 (22) 60 (17) 0.037 
Cardiovascular disease 203 (24) 20 (6) <0.001 
Diabetes 194 (23) 44 (12) <0.001 
Malignant disease 248 (30) 66 (19) <0.001 
End-stage renal failure 35 (4) 6 (2) 0.030 
Vascular/degenerative brain disease 72 (9) 4 (1) <0.001 
Main clinical manifestations, n (%)
Pneumonia 621 (75) 297 (83) 0.001 
Meningitis 87 (10) 25 (7) 0.065 
Peritonitis 35 (4) 16 (4) 0.816 
Other 91 (11) 18 (5) 0.001 
Prior PPV23 vaccination,c n (%) 127 (30) 34 (14%) <0.001 
Shock at presentation, n (%) 141 (17) 64 (18) 0.654 
30-day mortality, n (%) 159 (19) 46 (13) 0.010 
SD, standard deviation.
a One thousand three hundred and seventy-eight patients with IPD were divided into fo
who both smoked and abused alcohol (n = 142), and those who did not smoke and did
b p-Value shows the comparison of each category of smokers and alcohol abusers w
c 23-valent pneumococcal polysaccharide vaccine (PPV23). The numbers of patients w
127/422 in the control group, 34/239 in the smokers group, 0/21 in the alcohol abuserthose who abused alcohol (n = 46; 3%), those who both smoked
and abused alcohol (smokers–alcohol abusers) (n = 142; 10%),
and those who did not smoke or abuse alcohol (control group)
(n = 834; 61%).
Compared to the control group, patients who were smokers,
alcohol abusers, or smokers–alcohol abusers were younger, with a
higher proportion of males, and more often had certain underlying
diseases, such as chronic liver disease and HIV infection. Other
underlying diseases were usually less common in current smokers
and alcohol abusers than in the control group. In addition, smokers
more often suffered from pneumonia, and smokers–alcohol
abusers from peritonitis. Patients who were smokers, alcohol
abusers, or smokers–alcohol abusers had less frequently received
prior vaccination with PPV23 than the control group. Patients who
were alcohol abusers or smokers–alcohol abusers had a high
mortality rate (Table 1).
Taking into account all patients with IPD and including age,
sex, underlying diseases, smoking, alcohol abuse, clinical manifes-
tation, and shock in a multiple logistic regression model, alcohol
abuse remained independently associated with mortality (adjust-
ed OR 2.36, 95% CI 1.50–3.70), and current smoking did not
(adjusted OR 0.78, 95% CI 0.52-1.17).
3.3. Pneumococcal serotypes
As shown in Figure 2, serotypes 1, 8, and 23F were signiﬁcantly
more prevalent in smokers, while serotype 6C was more prevalent
in non-smokers; other serotypes that almost reached statistical
signiﬁcance were serotypes 3 (p = 0.067) and 4 (p = 0.061).
Serotypes 4, 11A, and 19F were signiﬁcantly more prevalent in
alcohol abusers than in alcohol non-abusers.
When analyzing the proportion of smoking and alcohol abuse
among patients infected with each serotype, compared with
serotype 3 as reference (Table 2), we observed that serotypes 1, 4,
8, and 23F showed a positive association with smoking and 6C a
negative association with smoking, and serotypes 4 and 11A a
positive association with alcohol abuse.ers and alcohol abusersa
Alcohol abusers
(n = 46)
p-Valueb Smokers and alcohol abusers
(n = 142)
p-Valueb
60.2  11.7 0.001 49.7  11.2 <0.001
43 (93) <0.001 127 (89) <0.001
3 (7) 15 (11)
34 (74) 0.168 111 (78) 0.276
14 (30) <0.001 50 (35) <0.001
3 (7) 0.083 37 (26) <0.001
9 (20) 0.677 25 (18) 0.220
5 (11) 0.036 9 (16) <0.001
11 (24) 0.919 19 (13) 0.008
7 (15) 0.035 26 (18) 0.005
0 0.251 1 (1) 0.050
0 0.027 1 (1) <0.001
36 (78) 0.564 105 (74) 0.896
1 (2) 0.076 7 (5) 0.040
3 (7) 0.443 18 (13) <0.001
6 (13) 0.653 12 (8) 0.378
0 0.001 10 (12) 0.001
8 (17) 0.932 38 (27) 0.005
13 (28) 0.126 42 (30) 0.004
ur categories: those who smoked (n = 356), those who abused alcohol (n = 46), those
 not abuse alcohol (control group) (n = 834).
ith the control group.
ho had received the PPV23/total numbers of cases with recorded information were:
s group, and 10/84 in the smokers–alcohol abusers group.
Figure 2. Distribution of pneumococcal serotypes among smokers (n = 498) and non-smokers (n = 880) (panel A), and among alcohol abusers (n = 188) and alcohol non-
abusers (n = 1190) (panel B) with invasive pneumococcal disease. Panel A: the asterisk (*) indicates a signiﬁcant difference between smokers and non-smokers: serotypes 1 (p
= 0.012), 6C (p = 0.002), 8 (p = 0.004), and 23F (p = 0.041). Panel B: the asterisk (*) indicates a signiﬁcant difference between alcohol abusers and alcohol non-abusers: serotypes
4 (p = 0.007), 11A (p = 0.003), and 19F (p = 0.036).
Table 2
Pneumococcal serotypes associated with smoking and alcohol abusea
Serotype Number of patients % Smokers OR (95% CI) % Alcohol abusers OR (95% CI)
3 144 29 Reference 13 Reference
1 103 48 2.20 (1.30–3.73) 13 0.95 (0.44–2.02)
4 54 48 2.25 (1.18–4.29) 26 2.30 (1.05–5.0)
5 47 38 1.50 (0.75–3.0) 11 0.78 (0.27–2.22)
6B 34 32 1.16 (0.52–2.59) 0 -
6A 28 36 1.34 (0.57–3.16) 4 0.24 (0.031–1.89)
6C 26 8 0.20 (0.04–0.89) 15 1.19 (0.37–3.85)
7F 87 41 1.71 (0.98–2.99) 13 0.95 (0.43–2.10)
8 40 57 3.28 (1.59–6.76) 13 0.94 (0.32–2.69)
9V 66 29 0.98 (0.51–1.86) 12 0.90 (0.37–2.19)
11A 24 46 2.05 (0.85–4.95) 33 3.28 (1.23–8.73)
12F 35 43 1.82 (0.85–3.89) 6 0.39 (0.08–1.79)
14 102 31 1.11 (0.64–1.92) 13 0.96 (0.45–2.04)
18C 30 37 1.40 (0.61–3.20) 17 1.31 (0.44–3.85)
19A 96 31 1.10 (0.63–1.93) 15 1.12 (0.53–2.36)
19F 62 39 1.53 (0.82–2.86) 23 1.91 (0.89–4.12)
22F 28 39 1.57 (0.67–3.63) 4 0.24 (0.03–1.89)
23F 41 51 2.55 (1.25–5.18) 17 1.35 (0.52–3.48)
24F 32 16 0.45 (0.16–1.24) 3 0.12 (0.02–1.64)
Others 265 33 1.20 (0.77–1.87) 15 1.13 (0.62–2.04)
Not done 34 41 1.70 (0.78–3.67) 12 0.87 (0.27–2.76)
a This table shows the odds ratio (OR) and 95% conﬁdence interval (95% CI) for each pneumococcal serotype (with more than 20 cases) using a logistic regression model.
In the ﬁrst analysis the dependent variable was smoking and in the second analysis the dependent variable was alcohol abuse. We chose serotype 3 as the reference, since it
was the most prevalent and because the proportions of smoking and alcohol abuse among patients infected with this serotype were near the average obtained for all IPD
patients.
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similar in smokers and non-smokers (64% and 62% of serotypes
causing IPD, respectively) and in alcohol abusers and alcohol non-
abusers (62% and 63% of serotypes causing IPD, respectively).
4. Discussion
The interaction between the human host and the pneumococ-
cus is a complex phenomenon, mainly because several pneumo-
coccal serotypes may cause IPD in children and adults.27–29 It has
been shown that several host conditions are risk factors for
pneumococcal infection, including age, immunosuppressive or
chronic diseases, alcohol and smoking habits, and prior viral
infections such as inﬂuenza virus.30,31
Some reports have shown that smoking and alcohol abuse are
quite prevalent in patients with IPD.2–4 For example, Nuorti et al.4
reported 58% smokers and 7% heavy alcohol drinkers among their
patients with IPD aged 18–64 years. The results of our study agree
with these reports and emphasize that smoking and alcohol abuse
habits are common among patients with IPD, and are more
prevalent than in the general population.
Smoking and alcohol abuse are particularly common in young
adults and males. However, it should be noted that a high
proportion of women with IPD were also smokers, but only a small
proportion were alcohol abusers (Figure 1). Indeed, patients with
IPD without underlying diseases are frequently smokers or alcohol
abusers.3
As expected, we found a strong association between smoking
and alcohol abuse in our study, since both habits often occurred in
the same person. This association could enhance the risk of IPD.
However, this interaction could not be investigated further since
the present study was not designed to explore risk factors for IPD.
This was not a case–control study comparing patients with and
without IPD.
Smokers and alcohol abusers with IPD more often had
underlying diseases such as HIV infection and chronic liver
disease, while other comorbidities occurred less frequently
(Table 1). Of note, chronic pulmonary disease was unexpectedly
less common in current smokers than in non-smokers with IPD,
but this may reﬂect the fact that this diagnosis is often made in
older adults who are former smokers.
As previously reported in patients with pneumonia,11 alcohol
abuse was associated with a higher mortality in our IPD patients. In
contrast, as compared to non-smokers, our current smokers with
IPD had no associated greater mortality (Table 1).
Certain serotypes causing IPD were more frequently associated
with smokers and alcohol abusers in this study (Figure 2). Although
the biological plausibility of these ﬁndings is unknown it might
suggest an interaction of smoking and alcohol habits with certain
serotypes. For example, one may speculate that host epithelial cells
damaged by tobacco12,13 may be easier to adhere to for some
speciﬁc serotypes and this may consequently lead to an increased
risk of IPD. In the same way, a poorer host immune response due to
increased alcohol intake may predispose to infections with certain
pneumococcal serotypes that have different virulence and
pathogenicity factors. Of note, the number of IPD cases for each
serotype was small in this study. Larger studies are needed in order
to determine the real association of some speciﬁc serotypes with
smoking and alcohol abuse habits.
Although our study was an observational clinical investigation
with its inherent limitations, it may have important implications
for the design and implementation of prevention strategies and
reinforces the current CDC recommendations for pneumococcal
vaccination of alcohol abusers and smokers.20 In the present study,
the serotype coverage (using data from 2002 to 2011) for the latest
PCV introduced, PCV13, was similar in smokers and non-smokersand in alcohol abusers and alcohol non-abusers, and about two-
thirds of IPD cases would have been covered with this vaccine.
In summary, smoking and alcohol abuse are the most
preventable risk factors for pneumococcal disease, particularly
in young adults. Thus, implementing smoking and alcohol abuse
cessation measures, controlling underlying diseases such as HIV,
preventing viral infections such as inﬂuenza virus, and introducing
an appropriate pneumococcal vaccination schedule should be
among the essential measures taken to prevent pneumococcal
infections and diminish the burden of pneumococcal disease.
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